BRPI0512869A - composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente - Google Patents
composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um pacienteInfo
- Publication number
- BRPI0512869A BRPI0512869A BRPI0512869-2A BRPI0512869A BRPI0512869A BR PI0512869 A BRPI0512869 A BR PI0512869A BR PI0512869 A BRPI0512869 A BR PI0512869A BR PI0512869 A BRPI0512869 A BR PI0512869A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- disorder
- disease
- patient
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 8
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 229940076279 serotonin Drugs 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- CNAFOLPGHNAMBW-UHFFFAOYSA-N indeno[2,1-b]pyrrole Chemical class C1=CC=CC2=CC3=NC=CC3=C21 CNAFOLPGHNAMBW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59204704P | 2004-07-29 | 2004-07-29 | |
| PCT/US2005/026415 WO2007081299A2 (en) | 2004-07-29 | 2005-07-26 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512869A true BRPI0512869A (pt) | 2008-04-08 |
Family
ID=37075566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512869-2A BRPI0512869A (pt) | 2004-07-29 | 2005-07-26 | composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20060025601A1 (enExample) |
| EP (1) | EP1841738A4 (enExample) |
| JP (1) | JP4990164B2 (enExample) |
| KR (2) | KR20130047765A (enExample) |
| CN (1) | CN101516372A (enExample) |
| AR (1) | AR050274A1 (enExample) |
| AU (1) | AU2005333518B2 (enExample) |
| BR (1) | BRPI0512869A (enExample) |
| CA (1) | CA2603249C (enExample) |
| IL (1) | IL180977A (enExample) |
| NO (1) | NO20071102L (enExample) |
| NZ (1) | NZ552806A (enExample) |
| RU (1) | RU2007107494A (enExample) |
| TW (1) | TWI377195B (enExample) |
| WO (1) | WO2007081299A2 (enExample) |
| ZA (1) | ZA200700684B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060025601A1 (en) | 2004-07-29 | 2006-02-02 | Athersys, Inc. | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators |
| JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| JP4866901B2 (ja) | 2007-02-07 | 2012-02-01 | 協和発酵キリン株式会社 | ３環系化合物 |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP3081213B1 (en) | 2008-08-06 | 2020-04-01 | Kyowa Kirin Co., Ltd. | Tricyclic compound |
| TW201041851A (en) | 2009-03-10 | 2010-12-01 | Organon Nv | Tricyclic heterocyclic derivatives |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN106380440B (zh) * | 2016-08-30 | 2019-02-01 | 华东师范大学 | 一种茚酮并吡咯类衍生物及其合成方法和应用 |
| CN106631989B (zh) * | 2016-11-26 | 2019-07-16 | 威海迪素制药有限公司 | 一种盐酸多奈哌齐有关物质e的制备方法 |
| WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3576334D1 (de) * | 1984-07-25 | 1990-04-12 | Abbott Lab | 1,2,3,3a,8,8a-hexahydro-indeno-(1,2-c)pyrrde. |
| US4622405A (en) * | 1984-07-25 | 1986-11-11 | Abbott Laboratories | 1,2,3,3a,8,8a-hexahydro-indeno[1,2-c]pyrroles useful in the treatment of hypertension |
| EP0422134B1 (en) * | 1988-12-15 | 1996-06-12 | Abbott Laboratories | 5-ht selective agents |
| US5049564A (en) * | 1989-11-17 | 1991-09-17 | Abbott Laboratories | 5-HT selective agents |
| US5244888A (en) * | 1989-11-17 | 1993-09-14 | Abbott Laboratories | 5-HT selective agents |
| TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
| US7351711B2 (en) * | 2003-07-31 | 2008-04-01 | Janssen Pharmaceutical, N.V. | Tricyclic indanyls as integrin inhibitors |
| TWI350168B (en) * | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| US20060025601A1 (en) * | 2004-07-29 | 2006-02-02 | Athersys, Inc. | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators |
-
2005
- 2005-07-26 US US11/189,952 patent/US20060025601A1/en not_active Abandoned
- 2005-07-26 JP JP2007554065A patent/JP4990164B2/ja not_active Expired - Fee Related
- 2005-07-26 KR KR1020137007788A patent/KR20130047765A/ko not_active Withdrawn
- 2005-07-26 CA CA2603249A patent/CA2603249C/en not_active Expired - Fee Related
- 2005-07-26 RU RU2007107494/04A patent/RU2007107494A/ru not_active Application Discontinuation
- 2005-07-26 NZ NZ552806A patent/NZ552806A/en not_active IP Right Cessation
- 2005-07-26 KR KR1020077002230A patent/KR101257233B1/ko not_active Expired - Fee Related
- 2005-07-26 AU AU2005333518A patent/AU2005333518B2/en not_active Ceased
- 2005-07-26 CN CNA2005800255071A patent/CN101516372A/zh active Pending
- 2005-07-26 WO PCT/US2005/026415 patent/WO2007081299A2/en not_active Ceased
- 2005-07-26 EP EP05858534A patent/EP1841738A4/en not_active Withdrawn
- 2005-07-26 BR BRPI0512869-2A patent/BRPI0512869A/pt not_active Application Discontinuation
- 2005-07-28 AR ARP050103146A patent/AR050274A1/es not_active Application Discontinuation
- 2005-07-29 TW TW094125988A patent/TWI377195B/zh not_active IP Right Cessation
-
2007
- 2007-01-24 ZA ZA200700684A patent/ZA200700684B/xx unknown
- 2007-01-25 IL IL180977A patent/IL180977A/en not_active IP Right Cessation
- 2007-02-27 NO NO20071102A patent/NO20071102L/no not_active Application Discontinuation
-
2009
- 2009-06-04 US US12/478,362 patent/US7935830B2/en not_active Expired - Fee Related
-
2011
- 2011-03-25 US US13/071,732 patent/US8232311B2/en not_active Expired - Fee Related
-
2012
- 2012-06-18 US US13/526,249 patent/US8716324B2/en not_active Expired - Fee Related
-
2014
- 2014-03-21 US US14/221,809 patent/US9096520B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Borges Filho et al. | Chrysin promotes attenuation of depressive-like behavior and hippocampal dysfunction resulting from olfactory bulbectomy in mice | |
| BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
| BRPI0512742A (pt) | composto, composição farmacêutica, e, método de tratamento de uma doença, distúrbio e/ou condição em um paciente em que modulação de uma função 5-ht2c é desejada | |
| BR112012022552A8 (pt) | uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos | |
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BRPI0518011A (pt) | uso de tetraidrocanabidivarina, métodos para o tratamento de uma doença ou condição e para cosmeticamente beneficiar a perda de peso, e, uso de um antagonista do receptor de canabinóide neutro | |
| BRPI0508820B8 (pt) | compostos moduladores de receptor de opióide e composição que os compreende | |
| BR112012018500A2 (pt) | alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas | |
| EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| BRPI0712976A2 (pt) | uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| NO20071102L (no) | Tricykliske indeno-pyrrolderivater som serotoninreseptormodulatorer | |
| BRPI0518798A2 (pt) | composto, composiÇço farmacÊutica, e, mÉtodos para tratar diabete tipo ii e para tratar uma condiÇço ou distérbio | |
| EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| EA200802020A1 (ru) | Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1 | |
| NO20082679L (no) | Sammensetning og fremgangsmate for a behandle CNS lidelser | |
| BR112013003847A8 (pt) | métodos de tratar a deterioração cognitiva moderada (mci) e os distúrbios relacionados | |
| EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
| BRPI0905687A8 (pt) | composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto | |
| DE60025604D1 (de) | Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| MA46342A (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| TW200621787A (en) | Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators | |
| BRPI0411608A (pt) | derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |